Halozyme Therapeutics opens European headquarters
Halozyme, a U.S. biotechnology company developing novel oncology and drug-delivery therapies, has established their European headquarters office in Basel, Switzerland.
“We evaluated several locations to set up our first European foothold and decided on Basel due to its outstanding biotechnology talent pool,” commented Laurie Stelzer, chief financial officer. “In Basel we found the right conditions – a top-notch life sciences talent pool, an overall attractive business environment and well-equipped lab space at the Technologie Park Basel.”
Basel, Switzerland is uniquely positioned as a life sciences location for companies along the entire value chain – from research to production and commercial stages. The location offers direct connections to the European market with its EuroAirport, state-of-the-art laboratory and manufacturing sites, and topped off with a 30’000 people-strong local life sciences workforce.
BaselArea.swiss is very pleased about Halozyme’s decision and welcomes the company to the local business community. The San Diego-based company is the latest of U.S. biotech companies to set up a European or global hub in the Basel region. Notable newcomers of 2016/17 are Ultragenyx, Roivant Sciences, W2O and Singulex.
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
Share this article
You might also be interested in
The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...Read More
Startups from the Basel Area have been ranked highly in the TOP 100 Swiss Startup Award by Venturelab. The medtech...Read More
The U.S. Food and Drug Administration has given the Basel-based life sciences company Roche authorization to use a test that...Read More
The Chinese life sciences company Hengrui Medicine is establishing a Swiss subsidiary in Basel. The European hub for clinical research...Read More
The Basel Area-based company Polyphor has signed an exclusive licensing agreement with Fosun Pharma in China. Fosun Pharma will lead...Read More
With the new “swiss hosting” label, the Basel-based company swiss made software Gmbh is guaranteeing that data will not be...Read More
Karin Crisanto recently joined Basel Area Business & Innovation as Head of Innovation Space and Infrastructure. She previously worked for...Read More